Fulgent GeneticsFLGT
FLGT
About: Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Employees: 1,313
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,222% more call options, than puts
Call options by funds: $8.39M | Put options by funds: $635K
100% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 2 (+1) [Q2]
18% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 50
16% more capital invested
Capital invested by funds: $276M [Q1] → $320M (+$44.1M) [Q2]
0% more ownership
Funds ownership: 52.86% [Q1] → 52.86% (+0%) [Q2]
6% less funds holding
Funds holding: 175 [Q1] → 165 (-10) [Q2]
26% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 27
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
2%
downside
Avg. target
$26
19%
upside
High target
$30
40%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
UBS Lu Li | 40%upside $30 | Buy Upgraded | 5 Aug 2025 |
Piper Sandler David Westenberg | 2%downside $21 | Neutral Maintained | 4 Aug 2025 |
Financial journalist opinion
Based on 5 articles about FLGT published over the past 30 days
Positive
The Motley Fool
3 weeks ago
Fulgent (FLGT) Q2 Revenue Jumps 16%
Fulgent (FLGT) Q2 Revenue Jumps 16%
Positive
The Motley Fool
3 weeks ago
Why Fulgent Genetics Stock Was Crushing It on Friday
Friday's stock market was generally a gloomy place, but apparently someone forgot to tell Fulgent Genetics (FLGT 7.80%). The company's shares were soaring in late-session action, with a very healthy rise of more than 8%.
Neutral
Seeking Alpha
3 weeks ago
Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Brandon Perthuis - Chief Commercial Officer Ming Hsieh - Chairman & CEO Paul Kim - Chief Financial Officer Conference Call Participants Andrew Harris Cooper - Raymond James & Associates, Inc., Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Lu Li - UBS Investment Bank, Research Division Lauren Sloane - The Blueshirt Group, LLC Operator Greetings, and welcome to the Fulgent Genetics Q2 2025 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Positive
Zacks Investment Research
3 weeks ago
Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.23 per share. This compares to earnings of $0.15 per share a year ago.
Neutral
Business Wire
3 weeks ago
Fulgent Reports Second Quarter 2025 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2025. Second Quarter 2025 Results: Total Revenue of $81.8 million Core Revenue1 grew 16% year-over-year to $81.7 million GAAP loss of $19.0 million, or ($0.62) per share Non-GAAP income of $2.1 million,.
Neutral
Business Wire
1 month ago
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received CE certification under the European Union (EU)'s In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) for its germline next-generation sequencing (NGS) system, which includes FulgentExome and Fulgent Pipeline Manager (PLM). Based on available i.
Neutral
Business Wire
1 month ago
Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer ques.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
GlobeNewsWire
2 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Charts implemented using Lightweight Charts™